Physiologic Regulation of FGF-23
Hypoparathyroidism
About this trial
This is an observational trial for Hypoparathyroidism focused on measuring Phosphate, Vitamin D, Hypoparathyroidism, Phosphatonin, Clamp
Eligibility Criteria
INCLUSION CRITERIA Adult hypoparathyroid patients, as defined by low or inappropriately normal PTH levels despite hypocalcemia, who are on a stable treatment regimen of calcitriol and calcium supplementation, and who are willing to participate in the study will be eligible. Adult PHP1B patients as defined by the clinical syndrome of elevated PTH and phosphorus and confirmed by methylation analysis of the GNAS gene. EXCLUSION CRITERIA Renal insufficiency as evidenced by a creatinine clearance of less than 50 ml/min Medically unstable patients Uncontrolled comorbid conditions, e.g., diabetes, coronary artery disease, congestive heart failure, or cerebrovascular disease. Digitalis therapy Patients on diuretic therapy, especially thiazides Pregnant and lactating women Patients whose hypoparathyroidism is caused by severe calcium-sensing receptor defects. These patients begin to have marked symptoms of "hypercalcemia" when the serum calcium is in the mid-normal range. Patients under 18 years of age Patients with history of any bone cancer, skeletal metastases or previous radiotherapy to the skeleton, unexplained elevations of serum alkaline phosphatase
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike